• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Ruth Tal-Singer, Anthony P. Cahn, +4 authors I J Pouliquen
  • Medicine
  • European journal of pharmacology
  • 2013 (First Publication: 15 February 2013)
  • To characterise the safety, tolerability, pharmacodynamics (bronchodilatory effect) and pharmacokinetics of inhaled umeclidinium in patients with chronic obstructive pulmonary disease (COPD). TheExpand
  • I J Pouliquen, Oliver Kornmann, Sharon V. Barton, Jeffrey A. Price, Héctor García Ortega
  • Medicine
  • International journal of clinical pharmacology…
  • 2015 (First Publication: 7 October 2015)
  • Objective: Mepolizumab is a humanized IgG1 monoclonal antibody that blocks human IL-5 from binding to the IL-5 receptor, which is mainly expressed on eosinophils. Eosinophils are key cells in theExpand
  • A. Sandler, M. Gordon, +10 authors C. Slapak
  • Medicine
  • Clinical Cancer Research
  • 2004 (First Publication: 15 May 2004)
  • Purpose: Our intention was to (a) to investigate the safety and tolerability of a potent P-glycoprotein modulator, zosuquidar trihydrochloride (LY335979), when administered i.v. alone or inExpand
  • Anthony P. Cahn, Ruth Tal-Singer, +5 authors Amanda Deans
  • Medicine
  • Clinical Drug Investigation
  • 2013 (First Publication: 20 June 2013)
  • BackgroundChronic obstructive pulmonary disease (COPD) has a significant negative impact on quality of life and increases the risk of premature death. Umeclidinium is a long-acting muscarinicExpand
  • Alan B. Sandler, Michael Q. Gordon, +10 authors Christopher A. Slapak
  • Medicine
  • Clinical cancer research : an official journal of…
  • 2004
  • PURPOSE Our intention was to (a) to investigate the safety and tolerability of a potent P-glycoprotein modulator, zosuquidar trihydrochloride (LY335979), when administered i.v. alone or inExpand
  • Prafull C. Mistry, Juliet Reid, +7 authors Elizabeth McKie
  • Medicine
  • International journal of clinical pharmacology…
  • 2014 (First Publication: 1 October 2014)
  • OBJECTIVE To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1070806, a novel IgG1 mAb that neutralizes human interleukin (IL)-18. METHODS In thisExpand